Synthetic Biologics is pioneering cutting-edge microbiome science designed to preserve the microbiome to protect and restore the health of patients.
Our two lead programs in late-stage clinical development are SYN-004 (ribaxamase), deigned to protect the natural gut microbiome to prevent antibiotic-mediated primary C. difficile infection (CDI), pathogenic overgrowth and the emergence of antimicrobial resistance (AMR) and SYN-010, designed to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).
We are a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients.
Our experienced management team has an extensive clinical and commercial track record.
ROCKVILLE, Md., Sept. 12, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage c
